Scientists track kidney Drug's journey through the body
NCT ID NCT07557407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This very early study (Phase 1) will give a single dose of a radioactive-labelled drug called HRS-1780 to 6 healthy men. The goal is not to treat disease but to track exactly how the drug is absorbed, broken down, and eliminated from the body. Results will help design future studies for chronic kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-1780 (a radioactive-labelled drug)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinan Central Hospital, Affiliated to Shandong First Medical University
Jinan, Shandong, 250013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a new drug combo shield young hearts from transplant complications?